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Summary
OBJECTIVES: Despite a broad and efficient pharmaco-
logical antihypertensive armamentarium, blood pressure
(BP) control is suboptimal and heterogeneous throughout
Europe. Recent representative data from Switzerland are
limited. The goal of the present survey was therefore to as-
sess the actual control rate of high BP in Switzerland in
accordance with current guidelines. The influence of risk
factors, target organ damage and medication on BP levels
and control was also evaluated.
METHODS: A cross-sectional visit-based survey of am-
bulatory hypertensive patients was performed in 2009 in
Switzerland. 281 randomly selected physicians provided
data on 5 consecutive hypertensive patients attending their
practices for BP follow-up. Data were anonymously col-
lected on demographics, comorbidities and current medic-
ation, and BP was recorded. Subsequent modification of
pharmacological antihypertensive therapy was assessed.
RESULTS: Data from 1376 patients were available. Mean
age was 65 ± 12 years, 53.9% were male subjects. 26.4%
had complicated hypertension. Overall, BP control (<140/
90 mm Hg for uncomplicated and <130/80 mm Hg for
complicated hypertension) was achieved in 48.9%. Com-
pared to patients with complicated hypertension, BP con-
trol was better in patients with uncomplicated hypertension
(59.4% vs. 19.2%, p <0.001). As a monotherapy the most
prescribed drug class were angiotensin receptor blockers
(ARB, 41%), followed by angiotensin converting enzyme
(ACE) inhibitors (21.5%), betablockers (20.8%) and calci-
um channel blockers (CCB, 10.8%). The most prescribed
drug combinations were ARB + diuretic (30.1%) and ACE
inhibitors + diuretic (15.3%). 46% were receiving a fixed
drug combination. In only 32.7% of patients with uncon-
trolled hypertension was a change in drug therapy made.
CONCLUSION: This representative survey on treated
adult hypertensive patients shows that, compared to earlier
reports, the control rate of hypertension has improved in
Switzerland for uncomplicated but not for complicated,
particularly diabetes-associated hypertension. ARBs and
ACE inhibitors are the most prescribed antihypertensive
drugs for monotherapy, whereas diuretics and ARBs were
the most used for combination therapy.
Key words: hypertension; uncomplicated hypertension;
complicated hypertension; hypertension control; blood
pressure control; visit-based survey; pharmacological
treatment; combination therapy; fixed combination
therapy
Introduction
Control of arterial hypertension in Europe [1–3] and the
United States [4] is far from optimal even though the arma-
mentarium of hypertension treatment has been substan-
tially broadened over the last 30 years. In a survey per-
formed in 2004 in different Western European countries as
well as in the United States, after the publication of the
hypertension guidelines promoting BP goals <140/90 mm
Hg [5], the BP normalisation rate was 31% in Italy, 26%
in the United Kingdom, 40% in Germany and in Spain,
46% in France and 63% in the United States. This, as
well as other studies, revealed a substantial heterogeneity
in the pharmacological treatment of elevated BP between
Europe and North America [1–3, 6, 7]. In the cross-section-
al EUROASPIRE III trial evaluating coronary heart disease
in patients <70 in 8 European countries, 60.9% of the pa-
tients had uncontrolled BP [8], and comparison with the
previous EUROASPIRE I and II showed an unchanged BP
control rate (58.1% and 58.3% respectively). In Switzer-
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land, the last available data on BP control in hypertensive
patients are almost 10 years old and refer to a cut-off value
for controlled hypertension based on the individual judg-
ment of the attending physician [9]. The objective of this
survey was therefore to evaluate current BP control rates in
adult hypertensive individuals in Switzerland and to com-
pare them with earlier reports. The influence of cardiovas-
cular risk factors, target organ damage and antihypertens-
ive medication on BP levels and hypertension control was
also evaluated.
Methods
Data collection
Data was collected in 2009 in Switzerland by performing a
cross-sectional survey of ambulatory patients visiting their
physicians. The randomisation of the participating physi-
cians was as follows: Switzerland was geographically di-
vided into 8 regions including 5 German-speaking, 2
French-speaking and 1 Italian-speaking region. For each
region, physicians were recruited randomly among general
practitioners, internists and cardiologists until the number
of 38 (34 for the Italian-speaking region) was reached.
The participating physicians were asked to give informa-
tion on the next five treated hypertensive patients aged >20
years attending their office. The inclusion criteria stated
that patients had to be hypertensive and were specially
treated for this condition for at least 3 months. Diagnosis
relied on the judgment of the attending physician and treat-
ment had not necessarily to be pharmaceutical, lifestyle
only being an acceptable alternative.
Information on demographic characteristics, history of hy-
pertension, current antihypertensive medication, presence
of target organ damage and cardiovascular risk factors was
collected by standardised questionnaire. In agreement with
previous studies [5], antihypertensive medication was clas-
sified as follows: angiotensin receptor blockers (ARB), cal-
cium channel blockers (CCB), betablockers, angiotensin
converting enzyme (ACE) inhibitors, diuretics and other
antihypertensive drugs.
Blood pressure measurement
In accordance with the guidelines [10], three consecutive
oscillometric BP readings at 1 min intervals were per-
formed in the seated position after a prior resting period
of at least 5 min. A BP measurement was also performed
after 2 min in the upright position. The physicians used
their own BP measuring devices and appropriate cuff di-
mensions were chosen according to the upper-arm circum-
ference. For statistical analysis the last two measured sit-
ting BP values were used.
The anonymous case report forms were collected by an in-
dependent data management office (Five Office ltd, Zurich,
Switzerland). All patients gave written informed consent.
The study was approved by regional ethical committees
throughout Switzerland.
Outcome measures
We analysed the BP data on the basis of three groups ac-
cording to the classification system of the 2007 ESH-ESC
guidelines [11]: BP <140 mm Hg, between 140 and 159
mm Hg and ≥160 mm Hg for systolic values and <90 mm
Hg, between 90 and 99 mm Hg and ≥100 mm Hg for dia-
stolic values. Hypertension control was defined as systol-
ic blood pressure (SBP) <140 mm Hg and diastolic blood
pressure (DBP) <90 mm Hg in patients with uncomplicated
hypertension and <130 mm Hg and <80 mm Hg in patients
with diabetes, chronic kidney disease (CKD) or protein-
uria. The influence of demographic factors, cardiovascu-
lar risk factors, comorbidities and pharmacotherapy on BP
levels and control was analysed. The effect of fixed com-
bination pharmacotherapy on BP control was also assessed.
Definition of comorbidities
The participating physicians were asked to report their pa-
tients’ cardiovascular comorbidities. Since no clear-cut
definition criteria of these comorbidities were applied, in-
terpretation and reporting of high-risk conditions such as
previous myocardial infarction or stroke, left ventricular
hypertrophy, CKD, proteinuria and microalbuminuria were
at the discretion of the physician involved. Diabetes mel-
litus was considered present if an antidiabetic therapy was
prescribed.
Statistical analyses
The Chi-squared test was used to compare relative frequen-
cies and Student’s t-test to compare mean values of two
groups. One-way ANOVA was used to compare the mean
difference between several groups. To indentify independ-
ent predictors of uncontrolled BP we performed a mul-
tivariate logistic regression analysis with inclusion of uni-
variate predictors (p <0.1) in the model by the forced entry
method. The analysis was performed using SAS/STAT
Software (SAS Institute Inc, Version 9.1).
Results
Patient characteristics
281 randomly selected physicians participated in this study,
181 general practitioners, 91 internists and 9 cardiologists.
A total of 1376 hypertensive patients were analysed.
The majority of patients included were recruited by general
practitioners (68%); 30% were recruited by internists and
2% by cardiologists.
Patient characteristics stratified according to systolic and
diastolic BP values are presented in tables 1 – 4. 74% of
the patients were overweight (body mass index [BMI] ≥25
kg/m2), and mean BMI was 28.8 ± 5.2 kg/m2.
73.4% of the patients included had uncomplicated hyper-
tension, while 26.4% had hypertension associated with dia-
betes mellitus, CKD and / or proteinuria. Among the pa-
tients with complicated hypertension, 83.4% had diabetes
mellitus, 24.7% proteinuria and 14.2% CKD. Compared
to patients with uncomplicated hypertension, patients with
complicated hypertension had more often left ventricular
hypertrophy (13.9% vs. 7.7%, p = 0.001), coronary revas-
cularisation (17.5% vs. 9.2%, p <0.001), previous myocar-
dial infarction (13.6% vs. 7.6%, p = 0.001), angina pectoris
(13.9% vs. 7.7%, p = 0.001), peripheral vascular disease
(13.3% vs. 5.3%, p <0.001), cerebrovascular disease
(11.3% vs. 7.9%, p = 0.049) and microalbuminuria (40%
vs. 7.9%, p <0.001).
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Influence of baseline characteristics on blood pressure
Average BP in patients with complicated hypertension was
138.8 ± 15.6 / 81.0 ± 10.0 mm Hg compared to 136.0 ±
15.3 / 82.1 ± 16.3 mm Hg in patients with uncomplicated
hypertension (p = 0.003 for SBP, fig. 1). There were sig-
nificantly more patients with complicated hypertension in
the subgroup with SBP levels ≥160 mm Hg compared to
the two other subgroups (34.6% vs. 30.2% vs. 22.9%, p =
0.003). 18.2% of the patients with uncomplicated hyperten-
sion had SBP ≥140 mm Hg in combination with DBP <90
mm Hg and 6.3% had SBP ≥150 mm Hg and DBP <90
mm Hg. Women were more likely than men to have isol-
Figure 1
Average systolic and diastolic blood pressure values in the different
subgroups of treated hypertensive patients (bar graph). The
diagram under the bar graph shows the rate of controlled
hypertension according to the individual blood pressure target in
the different subgroups. HT: hypertension. BP: blood pressure. SD:
standard deviation. * p <0.001, complicated vs uncomplicated
hypertension.
Figure 2
Pulse pressure by different age groups in treated hypertensive
patients.
Figure 3
Composition of the different fixed combination therapies used in the
study population. ACEI: angiotensin converting enzyme inhibitor;
CCB: calcium channel blocker; ARB: angiotensin receptor blocker;
Diur: diuretic; BB: betablocker; other: other antihypertensive
therapy.
ated systolic hypertension (21.7% vs. 15%, p = 0.006). Pa-
tients in the subgroup with SBP between 140 mm Hg and
159 mm Hg were older than patients in the group with SBP
<140 mm Hg (66.4 ± 11.6 years vs. 64.3 ± 11.8 years, p =
0.005). By contrast, patients with DBP <90 mm Hg were
significantly older than patients with DBP 90–99 mm Hg
(66.1 ± 11.8 years vs. 61.7 ± 11.6 years, p <0.001) and pa-
tients with DBP ≥100 mm Hg (66.1 ± 11.8 years vs. 60.6 ±
10.4 years, p <0.001). Thus, as expected, there was a signi-
ficant age-dependent pulse pressure increase (fig. 2). Cor-
respondingly, patients with isolated systolic hypertension
were older than patients without this condition (68.7 years
vs. 64.5 years, p <0.001).
BMI was significantly associated with DBP (p = 0.001) but
not SBP. Compared to the subgroups with higher SBP, dia-
betes (p = 0.026), proteinuria (p = 0.045), microalbumin-
uria (p = 0.005) and CKD (p = 0.013) were less frequent in
the subgroup with SBP <140 mm Hg. Myocardial infarc-
tion and coronary revascularisation were more frequent in
patients with DBP <90 mm Hg (p = 0.008 and p = 0.004
respectively) compared to subgroups with higher DBP.
Blood pressure control
Overall, 56.9% of the patients had BP measurements <140/
90 mm Hg and 19.6% had BP measurements <130/80 mm
Hg. Diabetes mellitus (24.9% vs. 19.2%, p = 0.012), mi-
croalbuminuria (21.5% vs. 14%, p = 0.002), proteinuria
(8.7% vs. 5.3%, p = 0.03) and CKD (5.1% vs. 2.9%, p
= 0.04) were more prevalent in patients with a BP ≥140/
90 mm Hg than in those with a BP <140/90 mm Hg.
Moreover, patients with coronary revascularisation or
myocardial infarction had BP ≥140/90 mm Hg (33.1% vs.
44.3%, p = 0.009 and 32% vs. 44.1%, p = 0.01, respect-
ively) less frequently than patients without these condi-
tions.
The proportion of hypertensive patients achieving indi-
vidual target values as recommended in the current
guidelines [10] and according to their low- or high-risk
status is shown in figure 1. Hypertension was uncontrolled
in 51% of the participants because target SBP was not
achieved in 19.5%, target DBP in 6.6% and both target
systolic and diastolic BP in 24.9% of patients.
Significantly fewer diabetic patients achieved BP target
(<130/80 mm Hg) compared to patients without diabetes
mellitus (19% vs. 57%, p <0.001). This proportion in-
creased to 50% if goal BP was set at <140/90 mm Hg but
remained statistically inferior to the 57% controlled hyper-
tensive patients without diabetes (p = 0.012). Moreover,
diabetes was more prevalent in the subgroup of patients
with uncontrolled compared to the subgroup of patients
with controlled hypertension (34.1% vs. 8.6%, p <0.001).
Similarly, patients with CKD, proteinuria or microalbu-
minuria reached BP goal significantly less frequently than
patients without CKD (20.4% in patients with CKD vs.
50.2% in patients without CKD, p <0.001), proteinuria
(16.2% vs. 51.6%, p <0.001) or microalbuminuria (28.7%
vs. 53%, p <0.001).
Not surprisingly, patients with a BMI <25 kg/m2 had a sig-
nificantly higher rate of controlled hypertension than over-
weight or adipose patients (54% vs. 47%, p = 0.029).
In a multivariate logistic regression analysis with inclusion
of BMI, diabetes, microalbuminuria and CKD and/or pro-
teinuria (nephropathy) as univariate predictors (p <0.1),
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and after adjustment for other variables, only diabetes (OR
5.1, 95% CI 3.7–7.1, p <0.001) and nephropathy (OR 3.3,
95% CI 2.0.–5.5, p <0.001) remained independently pre-
dictive of uncontrolled hypertension. The R2 for the model
was 0.15.
Medication
Overall, diuretics and ARBs were prescribed with the
greatest frequency (diuretics 51.7%, ARBs 51.4%), fol-
lowed by betablockers (36.2%), ACE-inhibitors (27.3%),
CCB (26.7%) and others (4.7%).
Detailed information on antihypertensive treatment accord-
ing to different BP subgroups is given in tables 5 and 6.
Overall, the mean duration of pharmacological antihyper-
tensive therapy was 9 ± 7.3 years. 1.6% of the patients
had no current drug therapy, 33.9% were treated with one,
36.8% with two, 20.4% with three and 7.2% with four or
more drug classes. As expected, complicated hypertension
was associated with the prescription of more drug classes
(p <0.001 vs. uncomplicated hypertension).
46.2% of the patients had at least one fixed combination
pill and 40.2% were treated by a free combination of drugs.
As a monotherapy, ARBs (41.0%) were used preferentially,
followed by ACE inhibitors (21.5%), betablockers
(20.8%), CCB (10.7%), diuretics (2.8%) and other drugs
(2.4%). Monotherapy by betablockers was more likely to
be prescribed in patients with prior myocardial infarction
or previous coronary revascularisation than in patients
without these comorbidities (48% vs. 19.3%, p = 0.001 and
37% vs. 19.9%, p = 0.033 respectively).
A combination ARB + diuretic was taken in 30.1% of all
patients, in 25.4% as a fixed combination. Corresponding
data for ARB + CCB were 12.7% and 4% respectively,
for ACE inhibitor + diuretic 15.3% and 11%, and for ACE
inhibitor + CCB 6.5% and 0.2% respectively. Among pa-
tients receiving a fixed combination therapy the most pre-
scribed drug association was ARB + diuretic (53%) fol-
lowed by other combinations (fig. 3).
Among diabetic patients, 58.3% were treated with a diuret-
ic, 50.7% with an ARB and 33.8% with an ACE inhibitor.
Compared to patients without diabetes, significantly more
patients with this risk factor received either an ARB or an
ACE inhibitor (82.1% vs. 76.5%, p = 0.037).
Prescription rates for patients not at goal for systolic BP
(isolated systolic hypertension under therapy) were 51.6%
for diuretics, 50.0% for ARBs, 38.6% for betablockers,
32.6% for CCBs and 22.3% for ACE inhibitors. These pa-
tients were more likely to be treated by a CCB compared to
patients without this condition.
BP was controlled in 11.8% of patients receiving no medic-
ation, in 53.8% treated by monotherapy, in 47.0% receiving
a fixed combination and in 47.3% treated by a free combin-
ation therapy.
Modification of antihypertensive drug regimen
As a result of the BP values measured at the study visit,
current antihypertensive drug therapy was changed in
18.2% of patients either by switching to a different drug
or by changing the existing dosage. Not surprisingly, treat-
ment adaptations were carried out more frequently in pa-
tients with uncontrolled compared to those with controlled
BP (32.7% vs. 6.4%, p <0.001). In 67.3% of patients in
whom BP was not controlled, no change in therapy was
made.
Table 1: Patient characteristics by systolic blood pressure subgroups.
Overall SBP <140 SBP 140 – 159 SBP ≥160 p-value
Frequency (%) 100.0 62.3 29.6 8.1
Male (%) 53.9 54 53.5 55.1 0.95
Age (years) 65.1 ± 11.9 64.3 ± 11.8 66.4 ± 11.6 66.1 ± 12.1 0.012
Average BP (mm Hg), sitting 137 ± 15/82 ± 15 127 ± 8/78 ± 9 147 ± 6/85 ± 9 170 ± 10/93 ± 13 <0.001
Heart rate (beats per minute) 72 ± 10 72 ± 13 72 ± 11 74 ± 11 0.168
Body mass index (kg/m2) 28.8 ± 5.2 28.7 ± 5.3 28.9 ± 5.1 29.2 ± 5.3 0.594
Family history of premature
cardiovascular disease (%)
27.4 27.0 28.7 26.0 0.77
Current smoker 22.9 22.1 24.5 23.4 0.66
Lipid lowering drugs (%) 45.2 45.1 45.9 43.9 0.93
Antidiabetic drugs (%) 21.6 19.4 24.2 29.0 0.026
BP: blood pressure; SBP: systolic blood pressure
Table 2: Patient characteristics by diastolic blood pressure subgroups.
Overall DBP <90 DBP 90–99 DBP ≥100 p-value
Frequency (%) 100.0 78.3 17.2 4.5
Male (%) 53.9 51.8 58.1 72.9 0.003
Age (years) 65.1 ± 11.9 66.1 ± 11.8 61.7 ± 11.6 60.6 ± 10.4 <0.001
Average BP (mm Hg), sitting 137 ± 15/82 ± 15 133 ± 13/78 ± 8 148 ± 14/93 ± 3 161 ± 17/106 ± 7 <0.001
Heart rate (beats per minute) 72 ± 10 71 ± 12 75 ± 10 78 ± 12 <0.001
Body mass index (kg/m2) 28.8 ± 5.2 28.5 ± 5.2 29.5 ± 5.6 30.7 ± 5.1 0.001
Family history of premature
cardiovascular disease (%)
27.4 27.7 27.6 22.8 0.72
Current smoker 22.9 22.1 24.8 29.3 0.34
Lipid lowering drugs (%) 45.2 47.2 40.4 28.8 0.006
Antidiabetic drugs (%) 21.6 21.2 22.7 25.4 0.69
BP: blood pressure; DBP: diastolic blood pressure
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Discussion
In this cross-sectional visit-based study conducted in 1376
treated adult hypertensive patients in Switzerland in 2009,
nearly three quarters had uncomplicated and one quarter
complicated hypertension. Among the latter group, more
than 80% were diabetic patients. The control rate of hy-
pertension was 49% overall, 59% in uncomplicated and
19% in complicated hypertension (fig. 1). It was also 19%
for the group of diabetic patients. The most prescribed an-
tihypertensive drug class, alone or in combination, were
ARBs and diuretics, followed by betablockers, ACE inhib-
itors, CCB and others.
Comparison of high BP control rates with earlier surveys
in Switzerland is difficult because the study design [12–14]
and/or the definitions of hypertension (control) [9, 14, 15]
employed differ. For example, a comparison with the last
available report, the prevalence, awareness, treatment and
control of high BP from Lausanne [12], is not possible be-
cause the survey was population-based and in the present
study it was visit-based. The difference is of major import-
ance since visit-based studies concentrate on treated hyper-
tensive patients visiting their physician, but ignore undia-
gnosed and untreated hypertensive patients and are likely
to report better control rates than population-based studies.
Moreover, in the CoLaus study BP was considered to be
controlled if its level was <140/90 mm Hg, without differ-
entiating between uncomplicated and complicated hyper-
tension [12], while in the present study differentiated blood
pressure goals are reported. When applying the same defin-
ition of BP control as that used in the CoLaus study, the
Table 3: Comorbidities by systolic blood pressure subgroups.
Overall SBP <140 SBP 140–159 SBP ≥160 p-value
Left ventricular hypertrophy1 (%) 24.0 22.7 25.8 28.2 0.35
Angina pectoris (%) 9.5 9.1 11.1 6.6 0.33
Previous myocardial infarction (%) 9.3 10.4 7.7 5.7 0.13
Coronary revascularisation (%) 11.5 12.8 10.5 4.7 0.039
Peripheral artery disease (%) 7.4 6.9 7.7. 9.3 0.64
Cerebrovascular disease (%) 8.8 8.0 10.5 8.4 0.35
Chronic kidney disease (%) 3.8 2.8 5.0 8.1 0.013
Proteinuria (%) 6.7 5.5 8.1 11.8 0.045
Microalbuminuria (%) 17.1 14.1 21.9 23.7 0.005
1 based on ECG or echocardiography. SBP: systolic blood pressure
Table 4: Comorbidities by diastolic blood pressure subgroups.
Overall DBP <90 DBP 90–99 DBP ≥100 p-value
Left ventricular hypertrophy1 (%) 24.0 24.1 22.0 30.4 0.48
Angina pectoris (%) 9.5 10.4 7.1 3.4 0.08
Previous myocardial infarction (%) 9.3 10.6 4.4 5.1 0.008
Coronary revascularisation (%) 11.5 13.0 5.8 6.8 0.004
Peripheral artery disease (%) 7.4 7.7 5.7 8.5 0.57
Cerebrovascular disease (%) 8.8 9.2 5.7 6.8 0.61
Chronic kidney disease (%) 3.9 4.1 3.3 1.9 0.63
Proteinuria (%) 6.7 6.7 6.8 7.1 0.99
Microalbuminuria (%) 17.1 16.1 22.2 15.4 0.17
1 based on ECG or echocardiography. DBP: diastolic blood pressure
Table 5: Antihypertensive medication by systolic blood pressure subgroups.
Overall SBP <140 SBP 140–159 SBP ≥160 p-value
Angiotensin receptor blocker (%) 51.4 51.9 49.6 52.3 0.75
Calcium channel blocker (%) 26.7 26.2 27.4 30.8 0.58
Betablocker (%) 36.2 35.2 36.3 41.1 0.48
Angiotensin converting enzyme inhibitor
(%)
27.3 28.5 26.3 24.3 0.54
Diuretic (%) 51.7 50.5 52.9 57.9 0.3
Others (%) 4.7 4.1 5.4 7.5 0.25
Fixed combination (%) 46.2 44.4 48.6 51.4 0.21
SBP: systolic blood pressure
Table 6: Antihypertensive medication by diastolic blood pressure subgroups.
Overall DBP <90 DBP 90–99 SBP ≥100 p-value
Angiotensin receptor blocker (%) 51.4 51.1 53.3 46.6 0.63
Calcium channel blocker (%) 26.7 28.3 21.1 25.9 0.09
Betablocker (%) 36.2 37.5 29.1 37.9 0.06
Angiotensin converting enzyme inhibitor
(%)
27.3 27.6 25.1 36.2 0.24
Diuretic (%) 51.7 52.9 47.1 50.0 0.28
Others (%) 4.7 4.5 5.3 6.9 0.66
Fixed combination (%) 46.2 47.1 42.7 44.8 0.49
DBP: diastolic blood pressure
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control rate increases to 59% in the current SWISSHYPE
study and compares favourably with the 48% reported in
the Lausanne cohort [12]. Using the same definition of
BP control (<140/90 mm Hg overall), the control rate in
SWISSHYPE is also higher than recently reported in other
western European countries (31–46%) [5] but lower than
in the United States [5]. Overall, compared to earlier re-
ports from Switzerland [9, 15] control of high BP seems
to have improved, particularly in uncomplicated hyperten-
sion. However, the reported data are not entirely objective
since they were provided by the attending physicians and
may therefore be prone to embellishment.
As expected [16], high BP was not controlled in most cases
(87.1%) because target SBP, isolated or jointly with target
DBP, was not reached. This chiefly reflects aging of the
population and its associated vessel stiffening (fig. 2) [16].
Moreover, and not surprisingly [17–19], compared to con-
trolled hypertensives, patients not at goal had higher BMI,
were more frequently diabetic, and had CKD more often.
Conversely, better BP control was found in patients with
established coronary heart disease. This finding is in agree-
ment with other studies [14, 20] and may reflect increased
attention of both physician and patient with regard to risk
factor management in secondary prevention [21].
In SWISSHYPE, 33.9% of the patients were treated by an-
tihypertensive monotherapy. Consequently, the remaining
two thirds of the patients were treated by multiple drug
classes including fixed combinations in 46.2% of cases or
freely combined antihypertensive drugs in 40.2%. In 2001,
as well as in a more recent survey from Lausanne, consid-
erably more hypertensive patients (57% and 69% respect-
ively) were treated by monotherapy in Switzerland [12,
15]. This change over time most probably reflects adheren-
ce to the newer guidelines [11, 22] which permit or even
recommend initiating antihypertensive treatment with low-
dose combination therapy (instead of performing sequen-
tial monotherapy).
Overall, the two most frequently prescribed drug classes
were ARBs (51.4%) and diuretics (51.7%). Similar results
were reported in the recent Swiss CoLaus study [12]. Thus,
ARB use is frequent in Switzerland compared to other
countries, where frequencies between 18–36% were repor-
ted [5]. This is in accordance with the guidelines of the
Swiss Society of Hypertension [22] and may reflect the
choice of the practitioners to prescribe a very well tol-
erated antihypertensive drug class which has similar an-
tihypertensive efficacy to other classes [23, 24]. It may
also reflect a trend towards early adoption of the newer
medications on the market by doctors or intense commer-
cial promotion [12]. Compared to data from Switzerland
from 2001, the most common agents used for monotherapy
have changed. Currently the class preferentially used were
ARBs followed by ACE inhibitors, betablockers, CCB and
diuretics, whereas in the earlier report the most frequently
prescribed category were ACE-inhibitors followed by
CCB, betablockers and hydrochlorothiazide [15]. The
present drug prescription pattern is not strictly in keeping
with the Swiss [22] or other hypertension guidelines [11,
25], especially with regard to the prescription of betablock-
ers. The rate of use of betablockers as a monotherapy in
SWISSHYPE is very similar to that recently reported in the
UK, where the prescription rate fell from 29% in 2003 to
21% in 2006 [26].
Fixed combination therapy was used in 46% of the treated
patients in the present SWISSHYPE survey. This rate
seems relatively high but due to lack of data comparison
with earlier Swiss reports or other European countries is
not possible. The preferred fixed combination prescribed
was by far the association of ARB + diuretic (53%) (fig. 3).
Among diabetic patients, 82.1% were treated with either an
ACE inhibitor (33.8%) or an ARB (50.7%). This is in keep-
ing with the guidelines [11, 22] but, even though the rate
of use of inhibitors of the renin-angiotensin system is fairly
good compared to other surveys [27–30], there is still room
for improvement even if taking into account the very few
diabetic patients who do not need such therapy and those
who do not tolerate it. Considering that diabetes-associated
hypertension is very often more salt-sensitive than other
forms of hypertension, the rate of diuretic use in the present
study (58.3%) seems low.
Diuretics and CCB are particularly efficacious and recom-
mended for the treatment of isolated systolic hypertension,
especially in elderly patients [11, 25]. In the current study,
33% of treated patients not at SBP target (<140 mm Hg)
were receiving CCBs and 52% diuretics.
The study has some limitations which have been discussed
and include the design (visit-based vs population-based),
the diagnostic criteria applied for hypertension and comor-
bidities (which all relied on the judgment of the attending
physician), the use of different BP-measuring devices (each
physician using his/her own device) and the possibly em-
bellished BP control results reported by the physicians.
In conclusion, this representative visit-based Swiss survey
on treated adult hypertensive patients shows that control
rates of hypertension have improved over time in Switzer-
land for uncomplicated but not for complicated, partic-
ularly diabetes-associated hypertension [9]. Compared to
earlier reports [12, 15], and in accordance with the newer
guidelines, more patients are treated by multiple antihyper-
tensive drug classes with 46% receiving a fixed combina-
tion. As a monotherapy, ARBs are the most frequently used
antihypertensive drug class, and betablockers represent the
third most prescribed category, this being not strictly in
keeping with the latest guidelines [11, 22]. Diuretics are
probably underused in diabetes-associated as well as in
isolated systolic hypertension, and more frequent use of
CCBs in isolated systolic hypertension may improve con-
trol rates in this difficult-to-treat category of hypertensive
patients. Finally, in as many as 67.3% of the uncontrolled
hypertensive patients, no change in pharmacological treat-
ment was made in the present SWISSHYPE survey.
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